# Radiation + Temozolomide Induced Mutation and Malignant Progression of GBM

> **NIH NIH R01** · NORTHWESTERN UNIVERSITY · 2020 · $270,375

## Abstract

   
DESCRIPTION (provided by applicant): The most common treatment for newly diagnosed glioblastoma (GBM) is surgical debulking of tumor followed by radiation therapy (RT) and chemotherapy with the DNA alkylator temozolomide (TMZ). Average survival for GBM patients treated in this manner is approximately 15 months, which is a time during which their tumor will recur, and no treatment has been identified that significantly improves the survival of patients with recurrent tumor. A central hypothesis associated with the studies proposed herein is that RT + TMZ therapy causes mutations in GBM, and that improved treatment of recurrent GBM requires a detailed understanding of these mutations. The research associated with this proposal will generate, characterize, and validate recurrent RT modified, TMZ modified, and RT + TMZ modified GBM tumor models that can be used by the principal investigator and others interested in the study and treatment of recurrent GBM.

## Key facts

- **NIH application ID:** 9882342
- **Project number:** 5R01NS095642-05
- **Recipient organization:** NORTHWESTERN UNIVERSITY
- **Principal Investigator:** Charles David James
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $270,375
- **Award type:** 5
- **Project period:** 2016-03-01 → 2022-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9882342

## Citation

> US National Institutes of Health, RePORTER application 9882342, Radiation + Temozolomide Induced Mutation and Malignant Progression of GBM (5R01NS095642-05). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/9882342. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*